MXPA02009744A - Uso de fulvestrant en el tratamiento de cancer resistente de mama. - Google Patents
Uso de fulvestrant en el tratamiento de cancer resistente de mama.Info
- Publication number
- MXPA02009744A MXPA02009744A MXPA02009744A MXPA02009744A MXPA02009744A MX PA02009744 A MXPA02009744 A MX PA02009744A MX PA02009744 A MXPA02009744 A MX PA02009744A MX PA02009744 A MXPA02009744 A MX PA02009744A MX PA02009744 A MXPA02009744 A MX PA02009744A
- Authority
- MX
- Mexico
- Prior art keywords
- fulvestrant
- treatment
- breast cancer
- resistant breast
- resistant
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title abstract 2
- 229960002258 fulvestrant Drugs 0.000 title abstract 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 abstract 2
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0008172.9A GB0008172D0 (en) | 2000-04-05 | 2000-04-05 | Therapy |
| PCT/GB2001/001500 WO2001074366A1 (en) | 2000-04-05 | 2001-04-02 | Use of fulvestrant in the treatment of resistant breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02009744A true MXPA02009744A (es) | 2004-02-26 |
Family
ID=9889101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02009744A MXPA02009744A (es) | 2000-04-05 | 2001-04-02 | Uso de fulvestrant en el tratamiento de cancer resistente de mama. |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20030158166A1 (enExample) |
| EP (2) | EP1272195B1 (enExample) |
| JP (1) | JP2003528919A (enExample) |
| KR (1) | KR100757764B1 (enExample) |
| CN (1) | CN1431905A (enExample) |
| AT (1) | ATE306270T1 (enExample) |
| AU (2) | AU2001244372B2 (enExample) |
| BR (1) | BR0109789A (enExample) |
| CA (1) | CA2403608A1 (enExample) |
| CH (1) | CH1272195H1 (enExample) |
| CZ (1) | CZ303096B6 (enExample) |
| DE (1) | DE60113975T2 (enExample) |
| DK (1) | DK1272195T3 (enExample) |
| EE (1) | EE05026B1 (enExample) |
| ES (1) | ES2248300T3 (enExample) |
| GB (1) | GB0008172D0 (enExample) |
| HU (1) | HU230064B1 (enExample) |
| IL (2) | IL151932A0 (enExample) |
| IS (1) | IS2869B (enExample) |
| MX (1) | MXPA02009744A (enExample) |
| NO (1) | NO329949B1 (enExample) |
| NZ (1) | NZ539603A (enExample) |
| PL (1) | PL201175B1 (enExample) |
| RU (1) | RU2265438C2 (enExample) |
| SK (1) | SK287779B6 (enExample) |
| UA (1) | UA80388C2 (enExample) |
| WO (1) | WO2001074366A1 (enExample) |
| ZA (1) | ZA200207538B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0116620D0 (en) * | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| CA2453111A1 (en) * | 2001-07-07 | 2003-01-23 | Alan Marshall Irving | Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| EP1623713A1 (en) * | 2004-07-09 | 2006-02-08 | Proskelia SAS | Cominations of pure anti-estrogen with aromatase inhibitors |
| US8557863B2 (en) * | 2005-09-27 | 2013-10-15 | Robert Benson Aylor | Suppression and prevention of tumors |
| WO2007062093A2 (en) * | 2005-11-22 | 2007-05-31 | Incyte Corporation | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor |
| US7910108B2 (en) * | 2006-06-05 | 2011-03-22 | Incyte Corporation | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
| US20140161827A1 (en) * | 2011-05-09 | 2014-06-12 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| CA2836831C (en) | 2011-05-20 | 2015-06-02 | Capital, Business Y Gestion De Finanzas S.L. | Pharmaceutical composition |
| US20160375234A1 (en) * | 2014-01-10 | 2016-12-29 | Atossa Genetic Inc. | Transpapillary methods and compositions for diagnosing and treating breast conditions |
| US9421264B2 (en) * | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| SG11202002105WA (en) | 2017-09-11 | 2020-04-29 | Atossa Therapeutics Inc | Methods for making and using endoxifen |
| WO2019224790A2 (en) * | 2018-05-24 | 2019-11-28 | Kashiv Biosciences, Llc | Prodrugs of fulvestrant |
| JP7662204B2 (ja) | 2019-07-03 | 2025-04-15 | アトッサ・セラピューティクス・インコーポレイテッド | エンドキシフェンの徐放性組成物 |
| EP4110344A4 (en) * | 2020-02-29 | 2024-03-13 | The University Of Vermont | Use of thyromimetics for the treatment of cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541669B1 (en) * | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
-
2000
- 2000-04-05 GB GBGB0008172.9A patent/GB0008172D0/en not_active Ceased
-
2001
- 2001-02-04 UA UA2002118734A patent/UA80388C2/uk unknown
- 2001-04-02 AU AU2001244372A patent/AU2001244372B2/en not_active Expired
- 2001-04-02 SK SK1429-2002A patent/SK287779B6/sk not_active IP Right Cessation
- 2001-04-02 RU RU2002129355/14A patent/RU2265438C2/ru active
- 2001-04-02 WO PCT/GB2001/001500 patent/WO2001074366A1/en not_active Ceased
- 2001-04-02 KR KR1020027013366A patent/KR100757764B1/ko not_active Expired - Lifetime
- 2001-04-02 CA CA002403608A patent/CA2403608A1/en not_active Abandoned
- 2001-04-02 PL PL357936A patent/PL201175B1/pl unknown
- 2001-04-02 JP JP2001572110A patent/JP2003528919A/ja active Pending
- 2001-04-02 HU HU0300339A patent/HU230064B1/hu unknown
- 2001-04-02 DE DE60113975T patent/DE60113975T2/de not_active Expired - Lifetime
- 2001-04-02 CZ CZ20023309A patent/CZ303096B6/cs not_active IP Right Cessation
- 2001-04-02 IL IL15193201A patent/IL151932A0/xx active IP Right Grant
- 2001-04-02 AT AT01917289T patent/ATE306270T1/de active
- 2001-04-02 NZ NZ539603A patent/NZ539603A/en not_active IP Right Cessation
- 2001-04-02 CN CN01810539A patent/CN1431905A/zh active Pending
- 2001-04-02 ES ES01917289T patent/ES2248300T3/es not_active Expired - Lifetime
- 2001-04-02 MX MXPA02009744A patent/MXPA02009744A/es active IP Right Grant
- 2001-04-02 AU AU4437201A patent/AU4437201A/xx active Pending
- 2001-04-02 BR BR0109789-0A patent/BR0109789A/pt not_active Application Discontinuation
- 2001-04-02 DK DK01917289T patent/DK1272195T3/da active
- 2001-04-02 EE EEP200200574A patent/EE05026B1/xx unknown
- 2001-04-02 EP EP01917289A patent/EP1272195B1/en not_active Expired - Lifetime
- 2001-04-02 CH CH01917289T patent/CH1272195H1/de unknown
- 2001-04-02 US US10/240,656 patent/US20030158166A1/en not_active Abandoned
- 2001-04-02 EP EP05007561A patent/EP1586323A1/en not_active Withdrawn
-
2002
- 2002-09-19 ZA ZA200207538A patent/ZA200207538B/en unknown
- 2002-09-25 IL IL151932A patent/IL151932A/en unknown
- 2002-10-01 IS IS6576A patent/IS2869B/is unknown
- 2002-10-02 NO NO20024735A patent/NO329949B1/no not_active IP Right Cessation
-
2010
- 2010-09-30 US US12/895,369 patent/US20110183949A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG148864A1 (en) | Methods of treating cancer and related methods | |
| HUS1500001I1 (hu) | ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére | |
| IL151932A0 (en) | Use of fulvestrant in the treatment of resistant breast cancer | |
| IL143870A0 (en) | Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia | |
| AU6147401A (en) | Compositions and methods for the treatment of cancer | |
| TW200612918A (en) | Lonidamine analogs | |
| MXPA05012421A (es) | Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos. | |
| HUP0203968A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| MY138883A (en) | Use of asiatic acid for treatment of cencer | |
| MXPA04003674A (es) | Uso mejorado de compuesto antitumoral en terapia de cancer. | |
| DE60324431D1 (de) | Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs | |
| MXPA03008582A (es) | Agentes y metodos para tratamiento de cancer. | |
| IL158206A0 (en) | Compositions and methods for the prevention and treatment of human prostate cancer | |
| GB0020504D0 (en) | Therapeutic method | |
| EP1320402A4 (en) | DEVICE FOR TREATING HEMORRHOIDS AND FOR PROSTATE MASSAGE | |
| BR0311146A (pt) | Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino | |
| HUP0301123A3 (en) | Use of exemestane for treatment of hormone-dependent breast cancer | |
| TW200503731A (en) | Method of treatment | |
| AU2003250912A8 (en) | Agents and methods for diagnosis and therapy of cancer and cancer risk assessment | |
| MXPA03002494A (es) | Metodo para reducir toxicidad de quimio terapias combinadas. | |
| EP1684795A4 (en) | METHODS AND AGENTS FOR THE TREATMENT OF CANCER | |
| SI1272195T1 (sl) | Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk | |
| UA28113C2 (uk) | Спосіб експрес-тестування ефективності реабілітації здоров'я людини | |
| UA34375A (uk) | Спосіб лікування рака молочної залози | |
| GB0115943D0 (en) | Treatment and diagosis of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD | Licence granted | ||
| FG | Grant or registration |